Document is current
Any future updates will be listed below
-
Authors
Parker, Helen
Ellison, Stuart M
Holley, Rebecca J
O'Leary, Claire
Liao, Aiyin
Asadi, Jalal
Glover, Emily
Ghosh, Arunabha
Jones, Simon
Wilkinson, Fiona L
Brough, David https://orcid.org/0000-0002-2250-2381
Pinteaux, Emmanuel
Boutin, Hervé
Bigger, Brian W https://orcid.org/0000-0002-9708-1112
-
Funding
Funding for this research was provided by:
Neuroscience Research Institute, University of Manchester
- License Information
-
More Information
Article History
Received: 24 July 2019
Revised: 15 January 2020
Accepted: 17 January 2020
First Online: 14 February 2020
Conflict of interest
: BB has shares and licensed programmes in enzyme replacement stem cell gene therapy for MPSIIIA and MPSIIIB to Orchard Therapeutics Ltd. BB has shares and licensed programme in enzyme replacement gene therapy for MPSIIIC to Phoenix Nest Inc. Neither conflict of interest competes with the content of this paper, which deals with pathophysiology‐ and inflammatory‐based treatment of MPSIIIA and other LSDs.
